Neurogene shares are trading higher after BMO Capital initiated coverage on the stock with an Outperform rating and announced a $65 price target.
Portfolio Pulse from Benzinga Newsdesk
Neurogene shares are trading higher after BMO Capital initiated coverage on the stock with an Outperform rating and announced a $65 price target.
June 27, 2024 | 4:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neurogene shares are trading higher after BMO Capital initiated coverage on the stock with an Outperform rating and announced a $65 price target.
The initiation of coverage by BMO Capital with an Outperform rating and a $65 price target is a strong positive signal for investors. This is likely to drive short-term buying interest and push the stock price higher.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100